Search company, investor...

Predict your next investment

Corporation
tamergroup.com

See what CB Insights has to offer

Investments

3

Portfolio Exits

1

Partners & Customers

3

About Tamer Group

Tamer Group is a healthcare, beauty care, prestige products, and fast moving consumer goods company. The Group's core activities are import, distribution, promotion, marketing and manufacturing.

Headquarters Location

Jeddah,

Saudi Arabia

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Tamer Group News

ASC Oncology GmbH. (11/1/22). "Press Release: ASC Oncology Proudly Announces New Partnership with Tamer Group". Berlin.

Nov 1, 2022

Organisation   Cancer does not stop at borders - and neither does an approach to personalized cancer therapy developed in Berlin. Reverse Clinical Engineering® is now available to oncologists and cancer patients in Saudi Arabia, the Middle East, and North Africa. Across borders, cancer is one of those diseases that is unpredictable, malignant and, despite high research efforts, not yet conquered. About 19.3 million people worldwide are diagnosed with cancer every year, and at the same time the prescribed chemotherapy fails in about half of all cancer patients. It is therefore essential to make advances in personalized cancer treatment available to doctors and cancer patients around the globe as quickly as possible and in a responsible manner. Therefore, the Berlin-based biotech company ASC Oncology GmbH ("ASC Oncology") thinks beyond borders and is committed to the international use of Reverse Clinical Engineering® test procedure. The possibility that patients and oncologists know, based on scientific data, which drug is likely to work for an individual patient before a drug therapy is started should become a matter of course worldwide. As an important next step in this journey, ASC Oncology today proudly announces its strategic partnership with Tamer Group. Through their century-long history, associated healthcare experience and the Tamer Group's large network in the Kingdom of Saudi Arabia, the Middle East and North Africa, the Reverse Clinical Engineering® testing procedure will thus become accessible to many patients as an important approach to personalized cancer therapy. Tumor researcher Dr. Christian Regenbrecht, co-developer of the Reverse Clinical Engineering® procedure, emphasizes the benefits of the new partnership for cancer patients and treating physicians: "For three years, we have been using the testing procedure to support oncologists and patients in optimally individualising cancer treatment. With Reverse Clinical Engineering®, we test different drug treatment options before starting therapy and thus find the therapy option that is most likely to have an effect on the individual patient's tumor. Outside the patient's body and thus without side effects. This is a key step on the road to establishing personalized cancer therapy, which we are now taking together with the Tamer Group." Reverse Clinical Engineering® enables oncologists to offer their patients effective therapy from the outset. Using a tissue sample of the patient's tumor taken during a biopsy or tumor surgery, 3D copies of the tumor, called organoids, are grown in the laboratory. In the next step, various cancer drugs are tested on these organoids to determine their effectiveness on the individual patient's tumor. In this way, on the one hand, a probably unsuccessful therapy can be prevented from unnecessarily burdening the cancer patient and, on the other hand, the chance of a therapeutic response can be significantly improved. Who is ASC Oncology? ASC Oncology was founded by nine leading scientists from the fields of expertise pathology, tumor biology, biochemistry, biotechnology and molecular biology in 2019 with the aim of addressing the most important challenge of modern oncology: Providing patients with the right therapy at the right time. In doing so, ASC Oncology scientists are stepping up to advance precision medicine internationally through the Reverse Clinical Engineering® procedure developed in Berlin to partner with oncologists to provide cancer patients with the best possible therapy from the start. Our goal is to provide better care to more patients than ever before in the history of oncology. ASC Oncology - Rethink Oncology. You will find the detailed press kit as well as press photos for your reporting in the press section of the website www.asc-oncology.com/press. If you have any questions, please do not hesitate to contact Melanie Alperstaedt at presse@asc-oncology.com or +49 30 235 9467 76. If you have any scientific questions or need an interview, she will be happy to arrange an expert interview with Dr. Christian Regenbrecht and other scientists from the ASC Oncology team.

Tamer Group Investments

3 Investments

Tamer Group has made 3 investments. Their latest investment was in Fetchr as part of their Bridge on July 7, 2020.

CBI Logo

Tamer Group Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

7/23/2020

Bridge

Fetchr

$15M

Yes

3

2/7/2018

Series B

Subscribe to see more

Subscribe to see more

10

11/18/2016

Series E

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/23/2020

2/7/2018

11/18/2016

Round

Bridge

Series B

Series E

Company

Fetchr

Subscribe to see more

Subscribe to see more

Amount

$15M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

10

10

Tamer Group Portfolio Exits

1 Portfolio Exit

Tamer Group has 1 portfolio exit. Their latest portfolio exit was SigFox on June 25, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/25/2021

Acquired

$99M

3

Date

6/25/2021

Exit

Acquired

Companies

Valuation

$99M

Acquirer

Sources

3

Tamer Group Acquisitions

1 Acquisition

Tamer Group acquired 1 company. Their latest acquisition was Mumzworld on June 28, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

6/28/2021

Series B

$99M

$32M

Corporate Majority

11

Date

6/28/2021

Investment Stage

Series B

Companies

Valuation

$99M

Total Funding

$32M

Note

Corporate Majority

Sources

11

Tamer Group Partners & Customers

3 Partners and customers

Tamer Group has 3 strategic partners and customers. Tamer Group recently partnered with ASC Oncology on November 11, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

11/1/2022

Partner

ASC Oncology GmbH. (11/1/22). "Press Release: ASC Oncology Proudly Announces New Partnership with Tamer Group". Berlin.

As an important next step in this journey , ASC Oncology today proudly announces its strategic partnership with Tamer Group .

1

7/21/2019

Partner

United States

Subscribe to see more

Subscribe to see more

10

Supplier

United States

Subscribe to see more

Subscribe to see more

10

Date

11/1/2022

7/21/2019

Type

Partner

Partner

Supplier

Business Partner

Country

United States

United States

News Snippet

ASC Oncology GmbH. (11/1/22). "Press Release: ASC Oncology Proudly Announces New Partnership with Tamer Group". Berlin.

As an important next step in this journey , ASC Oncology today proudly announces its strategic partnership with Tamer Group .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.